Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.
Ryan Kohlhepp of
What Happened? Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 3.7% in the afternoon session after a Reuters report indicated the US...
What Happened? A number of stocks jumped in the afternoon session after optimism improved supported by the U.S.-China trade summit and solid U.S. economic da...
Chime Financial delivered its first profitable quarter as revenue growth, margin expansion, and loan growth strengthened the fintech’s future prospects.
AeroVironment (NASDAQ:AVAV) Chairman, President and CEO Wahid Nawabi said accelerating global security threats are reshaping defense priorities toward drones, loitering munitions and counter-unmanned aircraft systems, areas where he said the company is well positioned.
Speaking at a Bank of America
Check out the companies making headlines yesterday: Nvidia (NASDAQ:NVDA): Leading designer of graphics chips Nvidia (NASDAQ:NVDA) rose by 2.7% on Wednesday a...
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome.
Love described A
What Happened? Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 2.7% in the afternoon session after sentiment improved fueled by a co...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year
Nebius shares are rallying as the company reported blockbuster Q1 financials – and even beyond headline numbers, there are ample reasons to load up on NBIS shares today.
What Happened? A number of stocks fell in the afternoon session after reports showed that wholesale inflation accelerated more sharply than anticipated in Ap...
The technology company's stock got a nudge from a big-name analyst. The fact that a major player in the technology space just became a shareholder, however, is an even-bigger deal.
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform.
Speaking at a Bank of
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Astrana Health (NASDAQ:ASTH) CEO and President Brandon Sim said the value-based care company is seeing early benefits from its acquisition of Prospect, while reporting stronger-than-expected first-quarter trends across medical costs, free cash flow and revenue.
Speaking at a Bank of America healthc
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.
Chief Executive Officer Cat
